Comprehensive Patient & Clinician Guide to Osimertinib 80mg (Tagrisso)

Osimertinib falls under the drug class of Tyrosine Kinase inhibitors and is used to treat non-small cell lung cancer (NSCLC), the most common form of lung cancer. As a third-generation medication, Osimertinib boasts enhanced efficacy in managing symptoms compared to its predecessors, offering new hope to patients with NSCLC.

Basic Information Regarding Osimertinib

• Osimertinib is popularly known by its brand name Tagrisso.
• Drug Class: Antineoplastic and kinase inhibitor.
• First Developed in: AstraZeneca started developing the drug in 2009, and it was completed in 2012.
• Regulatory Status: The molecule was approved by the FDA in 2015, and the branded Tagrisso received full approval in 2017.
• Method of Administration: Oral tablets.
• Chemical Formula: C28H33N7O2·CH4O3S

Uses of Osimertinib 80 Mg

Osimertinib is a targeted therapy primarily used to treat non-small cell lung cancer (NSCLC), a type of cancer characterized by the growth of abnormal cells in lung tissue.

The development of Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), addresses the challenge of tumor resistance to previous TKIs. Osimertinib is used to treat specific types of NSCLC, listed below:

• Adjuvant Therapy after Surgery: For patients who have undergone tumour removal surgery, Osimertinib helps prevent cancer recurrence in those with EGFR Exon 19 deletions or Exon 21 L858R mutations, as detected by FDA-approved tests.
• First-Line Treatment for Metastatic NSCLC: Osimertinib is prescribed to treat metastatic or advanced NSCLC. This means the cancer has spread to other parts of the body. It targets the specific EGFR inhibitors associated with abnormal cell signalling, leading to the rapid spread of cancer.
• Combined Therapy: In 2024, the FDA approved Osimertinib in combination with platinum-based chemotherapy.
• T790M Mutation: The abnormal cells responsible for cancer have developed resistance to the first- and second-generation TKIs. These cells are called T790M.
• Uses of Osimertinib: Osimertinib helps patients suffering from lung cancer live longer with Progression-Free Survival (PFS).

How Does Osimertinib Work?

Osimertinib stops the multiplication of cancer cells in the lungs and is often hailed as a life-saving drug. Here is its mechanism of action:

• Targets EGFR: The drug selectively targets the EGFR mutants, including Exon 19 Deletion, Exon 21 L858R, and T790. This ensures that the medicine does not bind to wild-type EGFR and thus limits toxicity.
• Binding: In the next course of action, the drug binds to the protein cysteine-797 at the ATP binding site. This process is irreversible and facilitated by the acrylamide group.
• Inhibits Mutant Activity: Osimertinib stops the cancer cells from sending production signals to other cells. This isolates the cells and causes them to die out eventually.
• The Osimertinib 80 stays in your system after 48 hours (half-life: 48 hours) and is eliminated through excretion and urination.

Potential Side Effects & Clinical Management Strategies

Because Osimertinib spares wild-type EGFR, it is generally better tolerated than first-generation TKIs, but side effects still require monitoring.

Serious Adverse Reactions (Require Immediate Emergency Care)

• Interstitial Lung Disease (ILD) / Pneumonitis: A rare (approximately 3–4%) but potentially life-threatening inflammatory lung reaction.

  • Symptoms: Sudden onset or worsening of shortness of breath, persistent dry cough, chest discomfort, or fever.

  • Action: Seek emergency medical care immediately. If ILD is diagnosed, Osimertinib must be permanently discontinued.

• QTc Interval Prolongation & Arrhythmias: Can alter cardiac electrical conduction, increasing the risk of ventricular arrhythmias.

  • Symptoms: Dizziness, lightheadedness, palpitations, chest fluttering, or fainting.

• Cardiomyopathy & Left Ventricular Dysfunction: Decrease in left ventricular ejection fraction (LVEF) or heart failure.

  • Symptoms: Shortness of breath, swelling in the ankles or lower legs, rapid unexplained weight gain.

• Ocular Toxicities (Keratitis): Inflammation of the cornea.

  • Symptoms: Eye pain, vision changes, increased sensitivity to light, watery or red eyes.

• Severe Cutaneous Reactions: Rare occurrences of Stevens-Johnson syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).

Precautions & Routine Safety Monitoring

Patients receiving Osimertinib require routine monitoring throughout their treatment cycle:

Drug Interactions & Special Population Protocols

Osimertinib is metabolized primarily by the hepatic enzymes CYP3A4 and CYP3A5.

Key Drug Interactions

• Strong CYP3A4 Inducers: Medications such as rifampin, carbamazepine, phenytoin, and St. John’s Wort accelerate the metabolism of osimertinib, significantly lowering its blood concentration and reducing its effectiveness. Co-administration should be avoided.

• Strong CYP3A4 Inhibitors: Medications like ketoconazole, itraconazole, and clarithromycin may increase osimertinib plasma concentrations. Monitor closely for adverse events.

• QT-Prolonging Medications: Use caution when co-administering with other drugs that prolong the QT interval (such as antiarrhythmics like amiodarone, or certain antipsychotics and antibiotics).

• Live Vaccines: Avoid receiving live attenuated vaccines during treatment due to the risk of infection.

Special Population Safety Guidelines

• Pregnancy (Strictly Unsafe): Osimertinib can cause fetal harm and pregnancy loss.

  • Female Patients: Must verify a negative pregnancy test prior to starting treatment and use effective non-hormonal contraception during therapy and for at least 6 weeks after the final dose.

  • Male Patients: Male patients with female partners of reproductive potential must use effective contraception during treatment and for at least 4 months after the final dose.

• Lactation: It is unknown whether osimertinib is excreted in human milk. Breastfeeding is contraindicated during treatment and for at least 2 weeks after the final dose.

• Geriatric Use (Age 65+): No overall differences in efficacy have been observed in older patients compared to younger adults, though side effects (such as diarrhea and skin reactions) may occur with higher frequency.

Available Brands and Formulations

Osimertinib is available in 40 mg and 80 mg film-coated oral tablets:

Frequently Asked Questions

Is Osimertinib chemotherapy?

Osimertinib is a targeted therapy drug and works differently from immunotherapy or chemotherapy.

Is Osimertinib covered by health insurance?

Osimertinib may be covered by health insurance if your plan specifies it. To get Osimertinib covered, you need prior authorization for the drug. Call your health insurance provider to get more details about your plan coverage.

How does Osimertinib work?

Osimertinib blocks the protein responsible for multiplying cancer cells. By blocking the epidermal growth factor receptor function of the cancer cell, it stops the cancer from spreading.

What does Osimertinib target?

It targets mutations in the EGFR gene such as exon 19 deletions, exon 21 L848R, and T790M.

When does Osimertinib stop working?

The drug typically stops working when the cancer develops resistance, making it ineffective.

What drug class is Osimertinib?

It belongs to the tyrosine kinase inhibitors and antineoplastic group of drugs.

Can you crush Osimertinib?

No, the drug should never be crushed or broken into halves for consumption. Swallow it with a glass of water.

When to take Osimertinib?

There is no fixed time to take Osimertinib; however, ensure you take it at regular intervals and at the same time every day.

Where to buy Osimertinib?

In the US, Osimertinib (Tagrisso) may only be available at specialty clinics or online pharmacies. You need a doctor’s prescription to buy this medicine.

Which company makes Osimertinib?

AstraZeneca Pharmaceuticals manufactures Osimertinib under the brand name Tagrisso. Other brands such as Incepta Pharmaceuticals, Everest Pharmaceuticals, and Beacon Pharmaceuticals also manufacture generic versions of Osimertinib.

Years of oncology research have yielded medicines like Osimertinib. Do not let lung cancer take control of your life. Buy Osimertinib from Indogenmed and start living your life freely!

Disclaimer: For information purposes only! Always consult a doctor and follow their guidelines.

References

1. National Center for Biotechnology Information (NCBI):

   • StatPearls Review: Osimertinib Pharmacology, Indications, and Clinical Applications. https://www.ncbi.nlm.nih.gov/books/NBK557620/

   • PMC Clinical Studies: Third-Generation EGFR-TKIs in Advanced Non-Small Cell Lung Cancer Management. https://pmc.ncbi.nlm.nih.gov/articles/PMC7323678/

2. U.S. Food and Drug Administration (FDA):

   • TAGRISSO (osimertinib) Full Prescribing Information & Safety Guidelines. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s031lbl.pdf

3. National Cancer Institute (NCI):

   • Osimertinib Mesylate Drug Dictionary & Research Summaries. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/osimertinib

4. Mayo Clinic:

   • Osimertinib (Oral Route) Description, Dosage & Precautions. https://www.mayoclinic.org/drugs-supplements/osimertinib-oral-route/description/drg-20165188

5. Medscape Reference:

   • Tagrisso (osimertinib) Dosing, Interactions & Adverse Effects. https://reference.medscape.com/drug/tagrisso-osimertinib-1000062